<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01554683</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000303</org_study_id>
    <nct_id>NCT01554683</nct_id>
  </id_info>
  <brief_title>Seizure Activity in Alzheimer's Disease</brief_title>
  <official_title>Seizure-like Hippocampal Activity in Alzheimer's Disease Neurodegeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this research project is to study how seizure-like activity affects the
      blood flow in the brain of patients with Alzheimer's disease (AD). Changes in blood flow can
      change memory and thinking ability, as happens in Alzheimer's disease. The investigators are
      using a study drug called Levetiracetam, which helps control seizure-like activity to see if
      it can help change the abnormal blood flow in the brain that is seen in some people with
      Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will make four separate visits to BIDMC. Subject will come to the Clinical Research
      Center. All of the visits will take around 5 hours apiece.

      If subjects agree to be in this study, subjects will be asked to read and sign the consent
      form. After subjects sign the consent form, the following things will happen:

        1. Screening Procedures: Screening procedures are tests and procedures that will be done to
           determine if subjects are eligible to take part in the research study. For this research
           study, the screening procedures include:

             -  A thorough medical history. Investigators will ask if subjects have any medical
                problems. Investigators will ask about subjects Alzheimer's disease and if they
                have had any seizures.

             -  A physical examination. Investigators will take your blood pressure and your heart
                rate. They will examine your heart and lungs and take your height and weight

             -  Investigators will also assess the subject's nervous system. Investigators will
                examine subject's speech, memory, strength, coordination, and reflexes.

             -  Investigators will ask you to take some paper and pencil tests. This will help us
                to understand your memory and mood

             -  Subjects will have a blood test to check how your kidneys are functioning.

           Subjects may have already had some of these tests done by their doctor when they were
           diagnosed with Alzheimer's disease.

           The information we learned will help to decide whether subjects could join the study.
           Investigators will explain the reason if they decide subjects should not join the study.
           Our decision does NOT mean that subjects have a health problem or disorder .

        2. Randomization Procedures: Investigators will meet with one of the study doctors if
           subjects continue in the study. The study doctor will explain to subjects when they are
           expected to come to the research center for study testing or to take the study drug.
           Subjects will come to the BIDMC Clinical Research Center for three visits. These visits
           will occur within one month.

           All study participants will receive the same study drugs over the three (3) visits.

             -  Subjects will receive levetiracetam, the study drug, in a low dose, 2.5 milligrams
                for each kilogram of body weight, at one visit.

             -  Subjects will receive levetiracetam, the study drug, in a high dose, 7.5 milligrams
                for each kilogram of body weight, at one visit.

             -  Subjects will receive a placebo at one visit.

           A placebo is an inactive injection that looks like the study drug, but a placebo
           contains no active medication. In this study, the placebo is a saline (sterile salt
           water) injection.

           Sometimes study results are truly due to the study medication. Sometimes the study
           results are not due to the study medication. Investigators are using a placebo to help
           us understand the reason for the results in this study.

           The order of the above visits will not be the same for all study participants. There are
           six different orders to receive the study drugs. For example, subjects could receive the
           placebo at the first visit, the high dose of levetiracetam at the second visit, and the
           low dose of levetiracetam at the third visit. Another example is that subjects could
           receive the low dose at the first visit, the placebo at the second visit, and the high
           dose at the third visit.

           Deciding the order in which you get the study drugs will be done by to a method called
           &quot;randomization.&quot; Randomization means that a computer will assign patients to study drugs
           in a random manner, like flipping a coin. Another way to say randomization is &quot;by
           chance.&quot; When you flip a coin, you get heads or tails by chance. The chance of getting
           any dose of study drug or placebo is about equal. After the randomization, Subjects will
           be assigned to get one study drug or placebo at each visit. Subjects will not be able to
           choose which study drug you will get at each visit.

           Subjects will not know which study drug dose or placebo will be given at a visit. The
           study doctor will not know which study drug dose or placebo will be given at a visit.
           The study doctor can find out this information quickly if there is an emergency.

        3. Research Procedures: Subjects will come to the BIDMC Clinical Research Center three
           times if they continue in this study. A member of the study team will meet subjects when
           they arrive. Subjects will first have an intravenous catheter (also called an IV) put
           into a vein. A nurse will check blood pressure and heart rate. Subjects will have a
           brief physical exam and a nervous system exam by a doctor

           Subjects will then have an electroencephalogram (EEG). An EEG gives investigators
           information about the nervous system - specifically the brain. Subjects will have their
           scalp cleaned with alcohol and small discs - called electrodes - placed on the scalp
           using gel. Then the head will be will be wrapped with gauze to. keep the discs from
           moving. The discs will be attached by wires to an EEG machine. The EEG machine will be
           at the bedside and will give investigators information about the electrical activity in
           the brain. Subjects will need to lie quietly with eyes closed during the one hour that
           the EEG machine is attached. Investigators will clean the gel from hair and skin when
           the EEG is over.

           Investigators will give subjects either levetiracetam -- the study drug -- or placebo
           while subjects are having EEG. Investigators will give subjects the study drug or
           placebo through the intravenous catheter (&quot;IV&quot;) in the arm. This will take around 20 to
           30 minutes. The subjects nurse will take the subject's blood pressure and heart rate two
           times while the study drug is being given to the subject and again after it is finished.
           The subject will note any side effects they have during this time and after.

           Subjects will then review what will happen during the MRI scan with the Investigator.
           The MRI study will be conducted at the Magnetic Resonance Imaging Center of the
           Department of Radiology at the Beth Israel Deaconess Medical Center.

           The MRI is a method of taking pictures of the brain and of the blood flow in the brain,
           using a large magnet and radio signals. Subjects will be asked to lie down on a platform
           that can be slid into the magnet. An MRI imaging coil, which is made from special wires
           that are covered in plastic, will be placed around the head. Foam pads will be placed
           around the head to limit head movement during the scan. During the scan, subjects will
           be asked to lie still on their back for about 45 to 60 minutes. They will hear a loud
           knocking or hammering noise while the MRI is taking pictures, but the process itself
           will be painless. They will be given disposable earplugs to use to help lessen the
           noise. During the procedure, subjects will be in constant contact with the MRI
           technician through an intercom. If at any time during the scan you feel too
           uncomfortable to continue, no matter what the reason, the study will be immediately
           stopped and subjects will be removed from the magnet (MRI Scanner).

           Subjects will return to the Clinical Research Center after the MRI. They will take a few
           pencil-and-paper tests for about one hour. These tests will tell the investigator about
           memory and mood. They will also learn about your attention skills. Investigators will
           also learn about the subjects= language skills and &quot;handedness&quot; (a tendency to favor
           right or left hand).

           As the medication (levetiracetam) may make the subject drowsy, they will not be able to
           drive. Someone will need to accompany them to and from the hospital for the three study
           visits.

           The second and third study visits will have the same sequence of events.

           SUMMARIES

           Here is a summary of the Screening Visit

           Screening visit / informed consent Review your medical history. Brief physical and
           neurological exam. Paper and pencil tests. Blood drawn to check the functioning of
           kidneys. Review and sign the informed consent form.

           Here are summaries of the three Study Visits

           Visit One

           :

           Vital signs. 2 minutes Brief physical and neurological exam. 10 minutes An intravenous
           catheter placed in your arm. 5 minutes EEG. 60 minutes Intravenous dose of the
           medication, levetiracetam, or placebo. 20 minutes MRI scan. 60 minutes Paper and pencil
           tests. 60 minutes

           Study Visit Two: (This visit will occur one to two (1-2 )weeks after Study Visit One)

           Vital signs. 2 minutes Brief physical and neurological exam. 10 minutes Intravenous
           catheter placed in your arm. 5 minutes EEG. 60 minutes Intravenous dose of the
           medication, levetiracetam, or placebo. 20 minutes MRI scan. 60 minutes Paper and pencil
           tests. 60 minutes

           Study Visit Three: (This visit will occur one to two (1-2 )weeks after Study Visit Two)

           Vital signs. 2 minutes Physical and neurological exam. 10 minutes Intravenous catheter
           placed in your arm. 5 minutes EEG. 60 minutes Intravenous dose of the medication,
           levetiracetam, or placebo. 20 minutes MRI scan. 60 minutes Paper and pencil tests. 60
           minutes

           Each visit will take a total of approximately 5 hours. This includes the time for the
           EEG, MRI imaging and neuropsychological tests. Subjects will be allowed time to rest
           between activities on a bed if they become tired. The CRC staff will serve lunch.

        4. Monitoring/Follow-Up Procedures. Procedures performed to evaluate the effectiveness and
           safety of the research procedures are called &quot;monitoring&quot; or &quot;follow-up&quot; procedures.
           Subject follow-up procedure will be a phone call from the study doctor one week after
           the third visit. They will ask if any side effects from the study or study medication
           occurred

      Timing: If subjects are enrolled into the study following the initial screening visit, each
      of the three study visits will be separated by 2-3 week intervals. Therefore, the entire
      study will last approximately 6-9 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Evaluable fMRI Scans</measure>
    <time_frame>3 MRIs acquired at visit 2,3 and 4 between weeks 1 and 6</time_frame>
    <description>Number of participants who had evaluable fMRI scans with arterial spin labeling to measure brain perfusion blood flow changes in specific brain regions, including the hippocampus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free and Cued Selective Reminding Test</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (one visit per intervention, visits spaced 2 weeks apart)</time_frame>
    <description>Evaluate memory changes, the free and cued selective reminding test lists the number of items recalled from a possibility of 16, adding free recall at two time points, yielding a score on a 0-32 scale per participant. A higher score is better, representing better recall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart</time_frame>
    <description>Evaluate AD severity, this is a 30 point scale from 0-30, with higher scores representing better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trial Making Test Parts A &amp; B</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
    <description>Evaluate visuo-spatial changes, outcome is total time to complete a task of connecting items (either numbers in trails A, or numbers alternating with letters in Trails B). A longer time indicates worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phonemic &amp; Category Fluency Test</measure>
    <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
    <description>Evaluate memory changes in AD. Phonemic fluency refers to the number of items generated in one minute beginning with a specific letter. A higher score indicates more items and better performance. There is no maximum score. Category fluency refers to the number of items generated belonging to a specific category (such as animals), again, more items generated indicates better performance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>High Dose Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Dose Levetiracetam administration via IV infusion over 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Levetiracetam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose Levetiracetam administration via IV infusion over 20 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administration via IV infusion over 20 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low/High/Placebo Dose Keppra (Levetiracetam)</intervention_name>
    <description>Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)</description>
    <arm_group_label>High Dose Levetiracetam</arm_group_label>
    <arm_group_label>Low Dose Levetiracetam</arm_group_label>
    <arm_group_label>Placebo administration</arm_group_label>
    <other_name>Levetiracetam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets the NINCDS-ADRDA criteria for probable Alzheimer's disease

          -  Mild AD (MMSE â‰¥ 20)

          -  Age &gt;= 50 years

          -  English as first language

        Exclusion Criteria:

          -  A history of seizures prior to the onset of AD

          -  Familial Alzheimer's Disease due to known genetic mutations

          -  Current use of an antiepileptic medication

          -  Current use of a medication known to lower seizure threshold (e.g. bupropion or a
             neuroleptic)

          -  Presence of parkinsonism

          -  Significant cerebrovascular disease

          -  Other Central Nervous System disease (e.g. stroke, severe traumatic brain injury)

          -  Major depression or other psychiatric or behavioral disorders (psychosis, agitation)

          -  Medical contraindication to MRI (e.g. pacemaker, intraocular or intracranial metallic
             objects)

          -  Severe claustrophobia or inability to lie flat for MRI

          -  Known allergy to levetiracetam, or history of previous adverse reaction to
             levetiracetam

          -  Serum creatinine &gt;= 2

          -  A score of &gt;9 on the Geriatric Depression Scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Press, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://tmslab.org/</url>
    <description>Berenson Allen Center Lab Website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <results_first_submitted>April 25, 2019</results_first_submitted>
  <results_first_submitted_qc>July 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 23, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Daniel Press</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Seizures</keyword>
  <keyword>Memory</keyword>
  <keyword>Executive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT01554683/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>While 12 participants were consented, 3 withdrew prior to receiving medications. 2 were due to claustrophobia preventing MRI and one was due to inability to recall why they were doing the study (so study was discontinued prior to drug administration).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Levetiracetam, Low Dose, Placebo</title>
          <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes followed by LEV at a dose of 2.5mg/kg over 20 minutes followed by Placebo over 20 minutes</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Levetiracetam, High Dose, Placebo</title>
          <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes followed by LEV at 7.5mg/kg over 20 minutes followed by Placebo</description>
        </group>
        <group group_id="P3">
          <title>Placebo Administration, High Dose LEV, Low Dose</title>
          <description>Saline administration via IV infusion over 20 min followed by LEV at 7.5mg/kg followed by LEV at 2.5 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>High Dose LEV, Placebo, Low Dose</title>
          <description>LEV at 7.5mg/kg followed by Placebo, followed by LEV at 2.5mg/kg</description>
        </group>
        <group group_id="P5">
          <title>Low Dose LEV, Placebo, High Dose LEV</title>
          <description>Low dose LEV at 2.5mg/kg followed by placebo followed by High Dose LEV at 7.5mg/kg</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Low Dose LEV, High Dose LEV</title>
          <description>Placebo, followed by low dose LEV at 2.5mg/kg followed by High dose LEV at 7.5mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Saline administration via IV infusion over 20 min, High dose LEV 7.5mg/kg, and Low dose LEV at 2.5mg/kg in random order</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Evaluable fMRI Scans</title>
        <description>Number of participants who had evaluable fMRI scans with arterial spin labeling to measure brain perfusion blood flow changes in specific brain regions, including the hippocampus</description>
        <time_frame>3 MRIs acquired at visit 2,3 and 4 between weeks 1 and 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Evaluable fMRI Scans</title>
          <description>Number of participants who had evaluable fMRI scans with arterial spin labeling to measure brain perfusion blood flow changes in specific brain regions, including the hippocampus</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>temporal lobe perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal lobe perfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free and Cued Selective Reminding Test</title>
        <description>Evaluate memory changes, the free and cued selective reminding test lists the number of items recalled from a possibility of 16, adding free recall at two time points, yielding a score on a 0-32 scale per participant. A higher score is better, representing better recall.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (one visit per intervention, visits spaced 2 weeks apart)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Free and Cued Selective Reminding Test</title>
          <description>Evaluate memory changes, the free and cued selective reminding test lists the number of items recalled from a possibility of 16, adding free recall at two time points, yielding a score on a 0-32 scale per participant. A higher score is better, representing better recall.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="10"/>
                    <measurement group_id="O2" value="14.3" spread="5.4"/>
                    <measurement group_id="O3" value="15" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment (MoCA)</title>
        <description>Evaluate AD severity, this is a 30 point scale from 0-30, with higher scores representing better performance.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment (MoCA)</title>
          <description>Evaluate AD severity, this is a 30 point scale from 0-30, with higher scores representing better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="1.7"/>
                    <measurement group_id="O2" value="21.4" spread="3"/>
                    <measurement group_id="O3" value="20.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trial Making Test Parts A &amp; B</title>
        <description>Evaluate visuo-spatial changes, outcome is total time to complete a task of connecting items (either numbers in trails A, or numbers alternating with letters in Trails B). A longer time indicates worse performance.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Trial Making Test Parts A &amp; B</title>
          <description>Evaluate visuo-spatial changes, outcome is total time to complete a task of connecting items (either numbers in trails A, or numbers alternating with letters in Trails B). A longer time indicates worse performance.</description>
          <units>seconds</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trails A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1" spread="14.7"/>
                    <measurement group_id="O2" value="47.1" spread="25.9"/>
                    <measurement group_id="O3" value="48.9" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trails B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.3" spread="44.4"/>
                    <measurement group_id="O2" value="138.9" spread="45.3"/>
                    <measurement group_id="O3" value="153.5" spread="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phonemic &amp; Category Fluency Test</title>
        <description>Evaluate memory changes in AD. Phonemic fluency refers to the number of items generated in one minute beginning with a specific letter. A higher score indicates more items and better performance. There is no maximum score. Category fluency refers to the number of items generated belonging to a specific category (such as animals), again, more items generated indicates better performance.</description>
        <time_frame>At visits 2,3,4 in weeks 1-6 (*one visit per intervention, visits spaced 2 weeks apart*</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Levetiracetam</title>
            <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Levetiracetam</title>
            <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
          </group>
          <group group_id="O3">
            <title>Placebo Administration</title>
            <description>Saline administration via IV infusion over 20 min</description>
          </group>
        </group_list>
        <measure>
          <title>Phonemic &amp; Category Fluency Test</title>
          <description>Evaluate memory changes in AD. Phonemic fluency refers to the number of items generated in one minute beginning with a specific letter. A higher score indicates more items and better performance. There is no maximum score. Category fluency refers to the number of items generated belonging to a specific category (such as animals), again, more items generated indicates better performance.</description>
          <units>Correct Items</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phonemic fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="12.5"/>
                    <measurement group_id="O2" value="34" spread="9.5"/>
                    <measurement group_id="O3" value="34.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Animal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="5.5"/>
                    <measurement group_id="O2" value="13.1" spread="3.7"/>
                    <measurement group_id="O3" value="12.4" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks, from beginning of study to end of study (study consisted of 3 separate infusions, all side effects were assessed over the 6 hours after the infusions)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Levetiracetam</title>
          <description>levetiracetam given at a dose of 7.5mg/kg over 20 minutes</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Levetiracetam</title>
          <description>Levetiracetam given at a dose of 2.5mg/kg over 20 minutes</description>
        </group>
        <group group_id="E3">
          <title>Placebo Administration</title>
          <description>Saline administration via IV infusion over 20 min</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Press</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-4074</phone>
      <email>dpress@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

